What is the 13F Pro Quality Score for ORGO?

13F Pro ranks Organogenesis Holdings Inc. (ORGO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ORGO's current score at https://13fpro.ai/research/ORGO (free sign-up required for the full ranking).

Which hedge funds own the most ORGO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ORGO include MORGAN STANLEY, Soleus Capital Management, L.P., BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ORGO as soon as new 13F filings post.

Where does 13F Pro source ORGO data?

All Organogenesis Holdings Inc. fundamentals and ownership data come directly from SEC EDGAR. Organogenesis Holdings Inc. files with the SEC under CIK 1661181. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ORGO in?

Organogenesis Holdings Inc. (ORGO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ORGO research updated on 13F Pro?

ORGO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Organogenesis Holdings Inc.(ORGO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1661181 ORGO stock profile & AI dashboard →

13F Pro Quality Score

20.5/100

Rank #2,673 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

14.9/100

Profitability

16.3/100

Balance Sheet

17.5/100

Earnings Quality

30.0/100

Free Cash Flow

18.3/100

Institutional Flow

11.8/100

Revenue Scale

32.7/100

Dilution Risk

38.4/100

ORGO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Organogenesis Holdings Inc. (ORGO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ORGO at 20.5/100 on a 32-signal composite quality model, placing it at rank #2,673 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (11.8) and revenue growth (14.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Organogenesis Holdings Inc. reports quarterly revenue of $37.2M, net income of $-53.2M, free cash flow of $18.0M. Top institutional holders of ORGO by reported 13-F value include MORGAN STANLEY, Soleus Capital Management, L.P., BlackRock,, based on the most recent SEC filings. ORGO trades on the Nasdaq exchange and files with the SEC under CIK 1661181. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Organogenesis Holdings Inc. directly from SEC EDGAR. Organogenesis Holdings Inc.'s 13F Pro composite quality score has ranged between 20 and 66 since 2021, currently 20.5 — a declining long-term trajectory across 27 quarterly and live scoring snapshots.

✦

Fun facts about Organogenesis Holdings Inc.

Quirks, history, and lore behind ORGO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · listed on Nasdaq · headquartered in Massachusetts · focused on regenerative medicine.
2
The Numbers
Annual revenue in the range of $200–250 million — small-cap territory — with a product portfolio spanning advanced wound care and surgical biologics.
3
The History
Founded in the 1980s, it was among the earliest companies to commercialize bioengineered human tissue, back when the idea sounded more like science fiction than surgery.
4
The Secret
Its products aren't drugs or devices in the traditional sense — they're living cell-based constructs and collagen matrices designed to help the body rebuild itself from the outside in.
5
The Lore
One of its flagship products, a bilayered cellular matrix, is essentially a lab-grown skin substitute used on diabetic foot ulcers and burns — real Frankenstein-but-make-it-helpful energy.
6
The Giveaway
The company's very name is a mashup of "organ" and "genesis" — because it literally grows human tissue replacements for a living, and its ticker is a tidy four-letter hint at that origin story.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$37.2M

Net Income

Q1 2026

$-53.2M

Free Cash Flow

Q1 2026

$18.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+30.3% YoY

$564.2MFY 2025

FY21 $467.4MFY22 $450.9MFY23 $433.1MFY25 $564.2M

Net Income

+648.9% YoY

$37.0MFY 2025

FY21 $94.2MFY22 $15.5MFY23 $4.9MFY25 $37.0M

Operating Income

+256.8% YoY

$44.7MFY 2025

FY21 $72.2MFY22 $22.3MFY23 $12.5MFY25 $44.7M

EPS (Diluted)

+275.0% YoY

$0.15FY 2025

FY21 $0.70FY22 $0.12FY23 $0.04FY25 $0.15

Total Assets

+30.2% YoY

$598.7MFY 2025

FY21 $443.3MFY22 $449.4MFY23 $460.0MFY25 $598.7M

Total Debt

—FY 2025

FY21 $74.1MFY22 $71.3MFY23 $66.6MFY25 —

Op. Cash Flow

-133.3% YoY

$-10.3MFY 2025

FY21 $62.0MFY22 $24.9MFY23 $30.9MFY25 $-10.3M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018
Revenue	$564.2M +30.3%	$433.1M -3.9%	$450.9M -3.5%	$467.4M +79.1%	$261.0M +34.9%	$193.4M
Net Income	$37.0M +648.9%	$4.9M -68.2%	$15.5M -83.5%	$94.2M +343.4%	$-38.7M +40.3%	$-64.8M
Operating Income	$44.7M +256.8%	$12.5M -43.8%	$22.3M -69.1%	$72.2M +341.9%	$-29.9M +42.1%	$-51.6M
EPS (Diluted)	$0.15 +275.0%	$0.04 -66.7%	$0.12 -82.9%	$0.70 +266.7%	$-0.42 +55.3%	$-0.94
Total Assets	$598.7M +30.2%	$460.0M +2.4%	$449.4M +1.4%	$443.3M +100.9%	$220.7M +34.8%	$163.7M
Total Debt	—	$66.6M -6.6%	$71.3M -3.8%	$74.1M +49.2%	$49.6M	—
Operating Cash Flow	$-10.3M -133.3%	$30.9M +24.4%	$24.9M -59.9%	$62.0M +284.9%	$-33.5M +44.7%	$-60.6M

AI Insight: ORGO Financial Trends

ORGO exhibits extreme quarterly volatility with revenue swinging from $226M in Q4 2025 to $37M in Q1 2026.

• Revenue peaked at $226M in Q4 2025 then crashed 84% to $37M in Q1 2026.

• Operating income swung from $63M profit in Q4 2025 to $69M loss in Q1 2026.

• Equity declined from $300M in Q4 2025 to $245M in Q1 2026 amid severe losses.

⚠ Revenue volatility suggests potential seasonal or one-time factors affecting business stability.

⚠ Operating cash flow turned positive to $21M in Q1 2026 despite massive operating losses.

AI Insight: ORGO Ratio Trends

ORGO's profitability collapsed in Q1 2026 with operating margin plummeting to -185.1% from 28.1% in Q4 2025.

• Operating margin swung from 28.1% in Q4 2025 to -185.1% in Q1 2026, a 213pp deterioration.

• ROE crashed from 58.2% in Q4 2025 to -86.9% in Q1 2026, erasing prior gains.

• Net profit margin fell to -142.8% in Q1 2026 from 19.4% in Q4 2025.

⚠ Extreme quarterly volatility in profitability metrics suggests operational instability or significant one-time charges.

⚠ Missing ROIC data in Q1 2026 amid severe margin compression limits visibility into capital efficiency.

Get alerted when ORGO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Organogenesis Holdings Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ORGO

MORGAN STANLEY
$27.5M11,616,795 sh
Soleus Capital Management, L.P.
$23.9M10,085,951 sh
BlackRock, Inc.
$11.6M4,899,751 sh
First Light Asset Management, LLC
$8.3M3,498,533 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.9M2,900,816 sh
DIMENSIONAL FUND ADVISORS LP
$6.9M2,891,006 sh
D. E. Shaw & Co., Inc.
$5.4M2,297,974 sh
Assenagon Asset Management S.A.
$4.7M1,967,952 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.2M1,783,964 sh
DEUTSCHE BANK AG\
$4.0M1,705,681 sh

Fund	Value	Shares
MORGAN STANLEY	$27.5M	11,616,795
Soleus Capital Management, L.P.	$23.9M	10,085,951
BlackRock, Inc.	$11.6M	4,899,751
First Light Asset Management, LLC	$8.3M	3,498,533
VANGUARD CAPITAL MANAGEMENT LLC	$6.9M	2,900,816
DIMENSIONAL FUND ADVISORS LP	$6.9M	2,891,006
D. E. Shaw & Co., Inc.	$5.4M	2,297,974
Assenagon Asset Management S.A.	$4.7M	1,967,952
GEODE CAPITAL MANAGEMENT, LLC	$4.2M	1,783,964
DEUTSCHE BANK AG\	$4.0M	1,705,681

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ORGO on your watchlist

Track score changes the day Organogenesis Holdings Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ORGO a good stock to buy?

13F Pro's AI-powered analysis of Organogenesis Holdings Inc. (ORGO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ORGO are available on the ORGO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ORGO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ORGO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Organogenesis Holdings Inc.'s investment landscape.